Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

together are uniquely positioned to help medical providers and patients understand the clinical promise and economic value of denosumab."

"This pioneering treatment that Amgen has developed will be a strong addition to our biopharmaceuticals portfolio," commented Andrew Witty, CEO of GlaxoSmithKline. "The data for denosumab is very encouraging and we believe it will provide significant benefit and value to patients with postmenopausal osteoporosis and other bone disease conditions. Together with Amgen we are committed to increasing worldwide access to this medicine."

In July 2007, Amgen granted Daiichi Sankyo exclusive rights to develop and commercialize denosumab in Japan in PMO and oncology with the potential for additional indications. This arrangement remains in place.

About Denosumab

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone. With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs.

Amgen has submitted marketing applications for denosumab in the United States, European Union, Canada, Switzerland, and Australia.

About Osteoporosis

Often referred to as the "silent epidemic," osteoporosis is a global problem that is
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... ONOM@TOPIC and SilOnIS shared the ... most innovative and sustainable project in the ... smartcard platform for,citizenship and mobile multimedia applications ... for users,while adding value for network operators. ...
... Investor Update Conference Call Set for March 7, ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,it has entered into ... the privately-held specialty pharmaceuticals marketer which,Senetek licensed in ...
... 4 Osteotech, Inc.,(Nasdaq: OSTE ), a ... for,regenerative medicine, announced today that the Food and ... its Plexur,M(TM) Biocomposite. Adapting the Company,s proprietary Plexur(R),Technology, ... bony voids or gaps,of the skeletal system that ...
Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Senetek PLC in Dispute With Marketer of Pyratine-6(TM) 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 3
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... University of Nottingham have taken some important first steps ... a leading science journal reports. Dr Cameron Alexander ... of Pharmacy have used polymers long-chain molecules ... surfaces of a real cell. In work published ...
... by clean, local-source energy. Faster, more reliable technologies ... language. Medical care tailored to your DNA, or ... diseases and injuries. Five University of Pittsburgh ... health, and technology as part of Faculty Early ...
... Researchers from Weill Cornell Medical College may have discovered ... the world,s most common blood disorders, beta-thalassemia, commonly known ... is the most commonly inherited disease in the world, ... of every 100,000 African-Americans. The World Health Organization estimates ...
Cached Biology News:Life, but not as we know it? 2Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 2Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 3Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 4
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: